Several predictive biomarkers have been identified and are routinely used in clinical practice. Some notable examples include:
EGFR mutations in non-small cell lung cancer, predicting response to tyrosine kinase inhibitors. KRAS mutations in colorectal cancer, indicating resistance to certain monoclonal antibodies. PD-L1 expression in various cancers, predicting response to immune checkpoint inhibitors.
